1,553
Views
34
CrossRef citations to date
0
Altmetric
Target Article

An Ethical Exploration of Barriers to Research on Controlled Drugs

, , , , , , & show all

REFERENCES

  • Abrams, D. I., C. A. Jay, S. B. Shade, et al. 2007. Cannabis in painful HIV-associated sensory neuropathy A randomized placebo-controlled trial. Neurology 68(7): 515–21.
  • Abrams, D. I. 1998. Medical marijuana: Tribulations and trials. Journal of Psychoactive Drugs 30(2): 163–69.
  • Aggarwal, S. K., G. T. Carter, M. D. Sullivan, C. ZumBrunnen, R. Morrill, and J. D. Mayer 2009.Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions. Journal of Opioid Management 5(3): 153–68.
  • Alexander, M. 2012. The new Jim Crow: Mass incarceration in the age of colorblindness. New York, NY: The New Press.
  • Alper, K. R., H. S. Lotsof, G. M. Frenken, D. J. Luciano, and J. Bastiaans. 1999. Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions 8(3): 234–42.
  • Anderson, E. E., and J. M. DuBois. 2012. IRB decision-making with imperfect knowledge: A framework for evidence-based research ethics review. Journal of Law, Medicine & Ethics 40(4): 951–69.
  • Anderson, E. E., and J. M. DuBois. 2007. The need for evidence-based research ethics: A review of the substance abuse literature. Drug and Alcohol Dependence 86(2): 95–105.
  • Anderson, E. E., S. Solomon, E. Heitman, et al. 2012. Research ethics education for community-engaged research: A review and research agenda. Journal of Empirical Research on Human Research Ethics 7(2): 3–19.
  • Andreae, M., D. Indyk, G. Carter, M. Johnson, K. Suslov, and H. Sacks. 2012. Lack of guidelines for use of medical marijuana for HIV neuropathic pain. Presented to American Public Health Association 140th Annual Meeting. American Public Health Association. https://apha.confex.com/apha/140am/webprogram/Paper265212.html.
  • Antonio, T., S. R. Childers, R. B. Rothman, et al. 2013. Effect of Iboga alkaloids on $$-opioid receptor-coupled G protein activation. PLoS ONE 8(10): e77262.
  • Bell, K., and A. Salmon. 2011. What women who use drugs have to say about ethical research: Findings of an exploratory qualitative study. Journal of Empirical Research on Human Research Ethics 6(4): 84–98.
  • Bernard, H. R. 2011. Research methods in anthropology: Qualitative and quantitative approaches. Lanham, MD: Rowman Altamira.
  • Berridge, V. 2009. Heroin prescription and history. New England Journal of Medicine 361(8): 820–21.
  • Winter, J. 2006. Weed control. Boston Globe, May 28. Available at: http://www.boston.com
  • Blackstone, S. 2012. Portugal decriminalized all drugs eleven years ago and the results are staggering. Business Insider International. Available at: http://www.businessinsider. com/portugal-drug-policy-decriminalization-works-2012-7 (accessedApril 20, 2015).
  • Boffey, P. M. 2014. What science says about marijuana. The New York Times, July 31, A22.
  • Bostwick, J. M. 2012. Blurred boundaries: The therapeutics and politics of medical marijuana. Mayo Clinic Proceedings 87(2): 172–86.
  • Bottorff, J. L., L. J. L. Bissell, L. G. Balneaves, J. L. Oliffe, N. Capler, and J. Buxton. 2013. Perceptions of cannabis as a stigmatized medicine: A qualitative descriptive study. Harm Reduction Journal 10:2.
  • Bulling, S., K. Schicker, Y.-W. Zhang, et al. 2012. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. Journal of Biological Chemistry 287(22): 18524–34.
  • Carter, A., and W. Hall. 2008. The issue of consent in research that administers drugs of addiction to addicted persons. Account Research 15(4): 209–25.
  • Castells, X., M. Casas, C. Pérez-Maсá, C. Roncero, X. Vidal, and D. Capellа. 2010. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews 2:CD007380.
  • Charland, L. C. 2002. Cynthia's dilemma: Consenting to heroin prescription. American Journal of Bioethics 2(2): 37–47.
  • Check, D. K., L. E. Wolf, L. A. Dame, and L. M. Beskow. 2014. Certificates of confidentiality and informed consent: Perspectives of IRB chairs and institutional legal counsel. IRB 36(1): 1–8. PubMed PMID: 24649737; PubMed Central PMCID: PMC4076050.
  • Cohen, P. J. 2010. Medical marijuana 2010: It's time to fix the regulatory vacuum. Journal of Law Medicine & Ethics 38(3): 654–66.
  • Cohen, P. J. 2009a. Medical marijuana: The conflict between scientific evidence and political ideology. Part two of two. Journal of Pain & Palliative Care Pharmacotherapy 23 (2):120–140.
  • Cohen, P. J. 2009b. Medical marijuana: The conflict between scientific evidence and political ideology. Part one of two. Journal of Pain & Palliative Care Pharmacotherapy 23(1): 4–25.
  • Costantino, C. M., A. Gupta, A. W. Yewdall, B. M. Dale, L. A. Devi, and B. K. Chen. 2012. Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS ONE 7(3): e33961.
  • Degenhardt, L., and W. Hall. 2012. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379(9810): 55–70. doi: 10.1016/S0140-6736(11)61138-0.
  • Diep, F. 2011. Clearing the smoke. Scientific American 305(4): 21–21.
  • Donnelly, J. R. 2011. The need for ibogaine in drug and alcohol addiction treatment. Journal of Legal Medicine 32(1): 93–114.
  • Drug Enforcement Administration. 2007. United States Code (USC) controlled substances act: Section 812. Schedules of controlled substances. GPO Access [www.gpoaccess.gov]. Office of Diversion Control, Drug Enforcement Administration.
  • Earleywine, M. 2005. Understanding marijuana: A new look at the scientific evidence. New York, NY: Oxford University Press.
  • Elia, N., and M. R. Tramèr. 2005. Ketamine and postoperative pain–a quantitative systematic review of randomised trials. Pain 113(1–2): 61–70.
  • Ellis, R. J., W. Toperoff, F. Vaida, et al. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology 34(3): 672–80.
  • Elsevier Connect. 2016. Research—not regulations—should guide medical marijuana use, journal editor says. Available at: https://www.elsevier.com/connect/research-not-regulations-should-guide-medical-marijuana-use-journal-editor-says.
  • Finnerup, N. B., S. H. Sindrup, and T. S. Jensen. 2010. The evidence for pharmacological treatment of neuropathic pain. Pain 150(3): 573–81.
  • Fleming, J. A., R. Byck, and P. G. Barash. 1990. Pharmacology and therapeutic applications of cocaine. Anesthesiology 73(3): 518–31.
  • Ghosh, S., A. Chandran, and J. P. Jansen. 2012. Epidemiology of HIV-related neuropathy: A systematic literature review. AIDS Research and Human Retroviruses 28(1): 36–48.
  • Gilbert, D.T., and J. E. Ebert. 2002. Decisions and revisions: The affective forecasting of changeable outcomes. Journal of Personality Social Psychology 82(4): 503–14.
  • Giles, M., and C. Workman. 2009. Clinical manifestations and the natural history of HIV. In HIV Management in Australia, 125–131. New South Wales, Australia: Australian Society for HIV Medicine.
  • Gligorov, N. 2009. Reconsidering the impact of affective forecasting. Cambridge Quarterly of Healthcare Ethics 18(2): 166–173; discussion 174–166.
  • Gossop, M., F. Keaney, P. Sharma, and M. Jackson. 2005. The unique role of diamorphine in British medical practice: A survey of general practitioners and hospital doctors. European Addiction Research 11(2): 76–82.
  • Greer, G., and R. Tolbert. 1986. Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs 18(4): 319–27.
  • Grinspoon, L., J. B. Bakalar, and R. Doblin. 1995. Marijuana, the AIDS wasting syndrome, and the U.S. government. New England Journal of Medicine 333(10): 670–71.
  • Halpern, J. and R. M. Arnold 2008. Affective forecasting: An unrecognized challenge in making serious health decisions. Journal of General Internal Medicine 23(10): 1708–1712.
  • Halpern, S. D., J. H. T. Karlawish, D. Casarett, J. A. Berlin, and D. A. Asch. 2004. Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials. Archives of Internal Medicine 164(7): 801–3.
  • Hamerle, M., L. Ghaeni, A. Kowski, F. Weissinger, and M. Holtkamp. 2014. Cannabis and other illicit drug use in epilepsy patients. European Journal of Neurology 21(1): 167–70.
  • Hammer, R. R., M. J. Dingel, J. E. Ostergren, K. E. Nowakowski, and B. A. Koenig. 2012. The experience of addiction as told by the addicted: Incorporating biological understandings into self-story. Culture Medicine and Psychiatry 36(4): 712–34.
  • Harrington, R. D., J. A. Woodward, T. M. Hooton, and J. R. Horn. 1999. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Archives of Internal Medicine 159(18): 2221–24.
  • Iskedjian, M., B. Bereza, A. Gordon, C. Piwko, and T. R. Einarson. 2007. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Current Medical Research and Opinion 23(1): 17–24.
  • Jacobson, R. 2014. Mystical medicine. Scientific American Mind 25(5): 24–24.
  • Kahneman, D., and A. Tversky. 2000. Choices, values, and frames. New York, NY: Cambridge University Press.
  • Kavalali, E. T., and L. M. Monteggia. 2012. Synaptic mechanisms underlying rapid antidepressant action of ketamine. American Journal of Psychiatry 169(11): 1150–56.
  • Kempner, J., C. S. Perlis, and J. F. Merz. 2005. Ethics. Forbidden knowledge. Science 307(5711): 854.
  • Kendall, J. M., B. C. Reeves, V. S. Latter, and Nasal Diamorphine Trial Group. 2001. Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures. British Medical Journal 322(7281): 261–65.
  • Kilmer, B., J. P. Caulkins, B. M. Bond, and P. H. Reuter. 2010. Reducing drug trafficking revenues and violence in Mexico: Would legalizing marijuana in california help? Santa Monica, CA: RAND Corporation. Available at: http://www.rand.org/pubs/occasional_papers/OP325; also available in print form.
  • Klitzman, R. 2006. From “male bonding rituals” to “suicide Tuesday”: A qualitative study of issues faced by gay male ecstasy (MDMA) users. Journal of Homosexuality 51(3): 7–32.
  • Klitzman, R. 2013. How IRBs view and make decisions about coercion and undue influence. Journal of Medical Ethics 39(4): 224–29.
  • Koenig, X., M. Kovar, S. Boehm, W. Sandtner, and K. Hilber. 2014. Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology 19(2): 237–39.
  • Koppel, B. S., J. C. M. Brust, T. Fife, et al. 2014. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82(17): 1556–63.
  • Kousik, S. M., T.. Napier, and P. M. Carvey. 2012. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Frontiers in Pharmacology 3:121.
  • Kramer, J. L. 2015. Medical marijuana for cancer. Ca-A Cancer Journal for Clinicians 65(2): 109–22.
  • Largent, E., C. Grady, F. G. Miller, and A. Wertheimer. 2013. Misconceptions about coercion and undue influence: Reflections on the views of IRB members. Bioethics 27(9): 500–7.
  • Li, J.-H., B. Vicknasingam, Y.-W. Cheung, et al. 2011. To use or not to use: An update on licit and illicit ketamine use. Substance Abuse and Rehabilitation 2:11–20.
  • Lutge, E. E., A. Gray, and N. Siegfried. 2013. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database of Systematic Reviews 4:CD005175.
  • Lynch, M. E., and F. Campbell. 2011. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology 72(5): 735–44. doi: 10.1111/j.1365-2125.2011.03970.x. Review. PubMed PMID: 21426373; PubMed Central PMCID: PMC3243008.
  • Macklin, R. 1981. On paying money to research subjects: ‘Due’ and ‘undue’ inducements. IRB 3(5): 1–6.
  • May, E. 1972. Narcotics addiction and control in Great Britain. Dealing with drug abuse: A report to the Ford Foundation. New York, NY: Praeger.
  • McAllister, W. B. 2004. The global political economy of scheduling: The international–historical context of the Controlled Substances Act. Drug and Alcohol Dependence 76(1): 3–8.
  • McInnes, R. J., E. Hillan, D. Clark, and H. Gilmour. 2004. Diamorphine for pain relief in labour: A randomised controlled trial comparing intramuscular injection and patient-controlled analgesia. BJOG 111(10): 1081–89.
  • Mondzac, A. M. 1984. In defense of the reintroduction of heroin into American medical practice and H.R. 5290—The Compassionate Pain Relief Act. New England Journal of Medicine 311(8): 532–35.
  • Musto, D. F. 1972. The marihuana tax act of 1937. Archives of General Psychiatry 26(2): 101–8.
  • Nahas, G. G., and A. Greenwood. 1974. The first report of the National Commission on marihuana (1972): Signal of misunderstanding or exercise in ambiguity. Bulletin of the New York Academy of Medicine 50(1): 55–75.
  • Nuijten, M., P. Blanken, W. van den Brink, and V. Hendriks. 2014. Treatment of crack-cocaine dependence with topiramate: A randomized controlled feasibility trial in The Netherlands. Drug and Alcohol Dependence 138: 177–84.
  • Nutt, D. J., L. A. King, and D. E. Nichols. 2013. Effects of schedule I drug laws on neuroscience research and treatment innovation. Nature Neuroscience 14(8): 577–85. doi: 10.1038/nrn3530. Epub 2013 Jun 12
  • O'Keefe, K. 2013. State medical marijuana implementation and federal policy. Journal of Helath Care Law & Policy 16: 39.
  • Oviedo-Joekes, E., S. Brissette, D. C. Marsh, et al. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine 361(8): 777–86.
  • Parrott, A. C. 2007. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): An evidence-based review. Psychopharmacology (Berlin) 191(2): 181–93.
  • Publications.parliament.uk. 2015. House of Commons—Science and technology—Written evidence. Available at: http://www.publications.parliament.uk/pa/cm200506/cm (accessed January 22, 2015).
  • Ransom, J. 1999. “Anslingerian” politics: The history of anti-marijuana sentiment in federal law and how Harry Anslinger's anti-marijuana politics continue to prevent the FDA and other medical experts from studying marijuana's medical utility. Available at: https://dash.harvard.edu/handle/1/8965561
  • Rhodes, R. 2002. Unsafe presumptions in clinical research. American Journal of Bioethics 2(2): 49–51.
  • Rhodes, R. 2006. Why test children for adult-onset genetic diseases? Mt Sinai Journal of Medicine 73(3): 609–616.
  • Rhodes, R. and J. J. Strain 2008. Affective forecasting and its implications for medical ethics. Cambridge Quarterly of Healthcare Ethics 17(1): 54–65.
  • Rhodes, R. and J. J. Strain. 2009. Further thoughts about affective forecasting biases in Medicine: A response to Nada Gligorov. Cambridge Quarterly of Healthcare Ethics 18(2): 174–176.
  • Roback, M. G., J. E. Wathen, T. MacKenzie, and L. Bajaj. 2006. A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Annals of Emergency Medicine 48(5): 605–12.
  • Robertson, K., C. Bayon, J.-M. Molina, et al. 2014. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care 26(12): 1555–61.
  • Ross S. 2012. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clinics of North America 35(2): 357–74. doi: 10.1016/j.psc.2012.04.002.
  • Savulescu, J. 2001. The fiction of“ undue inducement”: Why researchers should be allowed to pay participants any amount of money for any reasonable research project. American Journal of Bioethics 1(2): 1g–3g.
  • Sawynok, J. 2014. Topical and peripheral ketamine as an analgesic. Anesthesia and Analgesia 119(1): 170–178.
  • Scientific American. 2014. End the drug war's research bans. 310(2): 10. doi:10.1038/scientificamerican0214-10. Available at: http://www.scientificamerican.com/article/end-the-ban-on-psychoactive-drug-research/
  • Sessa, B. 2007. Is there a case for MDMA-assisted psychotherapy in the UK? Journal of Psychopharmacology 21(2): 220–24.
  • Silva, E. M., C. C. Cirne-Santos, I. C. Frugulhetti, et al. 2004. Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta Medical 70(9): 808–12.
  • Sindicich, N., L. Degenhardt, and W. Hall. 2010. The use of MDMA for therapeutic purposes. In L. Degenhardt and W. Hall, eds. The health and psychological effects of ecstasy (MDMA) use. Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
  • Swartz, J. 2012. Substance abuse in America: A documentary and reference guide, 259. Westport, CT: Greenwood.
  • Turk, D. C., M. C. Brody, and E. A. Okifuji. 1994. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 59(2): 201–8.
  • United States Congress. 1980. Foreign Commerce. Subcommittee on Health. Therapeutic Use of Heroin: Hearing Before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, Second Session, on HR 7334. September 4, 1980.: US Government Printing Office, 1980.
  • Volkow, N. D., R. D. Baler, W. M. Compton, and S. R. B. Weiss. 2014. Adverse health effects of marijuana use. New England Journal of Medicine 370(23): 2219–27.
  • Ware, M. A., T. Wang, S. Shapiro, et al. 2010. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Canadian Medical Association Journal 182(14): E694–E701.
  • Wax-Thibodeaux, E. 2014. Federal research seeks alternatives to addictive opioids for veterans in pain. Washington Post. Avaialble at: https://www.washingtonpost.com/news/federal-eye/wp/2014/09/25/federal-research-seeks-alternatives-to-addictive-opioids-for-veterans-in-pain/
  • Wee, M. Y. K., J. P. Tuckey, P. Thomas, and S. Burnard. 2011. The IDvIP trial: A two-centre randomised double-blind controlled trial comparing intramuscular diamorphine and intramuscular pethidine for labour analgesia. BMC Pregnancy Childbirth 11:51.
  • Wee, M. Y. K., J. P. Tuckey, P. W. Thomas, and S. Burnard. 2014. A comparison of intramuscular diamorphine and intramuscular pethidine for labour analgesia: A two-centre randomised blinded controlled trial. BJOG 121(4): 456.
  • Wilsey, B., T. Marcotte, R. Deutsch, B. Gouaux, S. Sakai, and H. Donaghe. 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain 14(2): 136–48.
  • Wilson, T. D., T. Wheatley, J. M. Meyers, D. T. Gilbert DT, and D. Axsom. 2000. Focalism: A source of durability bias in affective forecasting. Journal of Personality and Social Psychology 78(5): 821–36.
  • Yau, G. L., C. S. Jackman, P. L. Hooper, and T. G. Sheidow. 2011. Intravitreal injection anesthesia–comparison of different topical agents: A prospective randomized controlled trial. American Journal of Ophthalmology 151(2): 333–37.e2.
  • Zinberg, N. E., and J. A. Robertson. 1972. Drugs and the public. New York, NY: Simon and Schuster.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.